Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07600151 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

Study acronym: CONQUISTADOR
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.
Trial Details
NCT Number NCT07600151
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Collaborators: AbbVie, Sanofi
Conditions
(from sponsor)		 Myeloma Multiple, Myeloma
Related terms Multiple Myeloma, Neoplasms, Plasma Cell
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov